BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Das S, Amin SA, Jha T. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies. Eur J Med Chem 2021;223:113623. [PMID: 34157437 DOI: 10.1016/j.ejmech.2021.113623] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 8.5] [Reference Citation Analysis]
Number Citing Articles
1 Borges MADH, Passos FRS, Quintans JSS, Azeredo FJ. Hecogenin and its derivates: A pharmacology review. Biomed Pharmacother 2023;159:114251. [PMID: 36641922 DOI: 10.1016/j.biopha.2023.114251] [Reference Citation Analysis]
2 Hashemi M, Mirdamadi MSA, Talebi Y, Khaniabad N, Banaei G, Daneii P, Gholami S, Ghorbani A, Tavakolpournegari A, Farsani ZM, Zarrabi A, Nabavi N, Zandieh MA, Rashidi M, Taheriazam A, Entezari M, Khan H. Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents. Pharmacol Res 2023;187:106568. [PMID: 36423787 DOI: 10.1016/j.phrs.2022.106568] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jo HW, Kim MM. β-Caryophyllene oxide inhibits metastasis by downregulating MMP-2, p-p38 and p-ERK in human fibrosarcoma cells. J Food Biochem 2022;46:e14468. [PMID: 36190169 DOI: 10.1111/jfbc.14468] [Reference Citation Analysis]
4 El‐hussieny M, Mansour ST, Hashem AI, Fouad MA, Abd‐el‐maksoud MA. Design, synthesis, and biological evaluation of new heterocycles bearing both silicon and phosphorus as potent MMP ‐2 inhibitors. J Chinese Chemical Soc 2022. [DOI: 10.1002/jccs.202200327] [Reference Citation Analysis]
5 Fang X, Li S, Liu H, Han W, Li Y, Yu X, Li Q. Association between the reduced expression of RECK and neutrophilic inflammation in chronic obstructive pulmonary disease.. [DOI: 10.21203/rs.3.rs-2126801/v1] [Reference Citation Analysis]
6 Wang Q, Cui H, Gan N, Ma X, Ren W, Wu A. Recent advances in matrix metalloproteinases-responsive nanoprobes for cancer diagnosis and therapy. Reviews in Analytical Chemistry 2022;41:198-216. [DOI: 10.1515/revac-2022-0044] [Reference Citation Analysis]
7 Wu W, Li X, Qi M, Hu X, Cao F, Wu X, Fu J. Cordycepin Inhibits Growth and Metastasis Formation of MDA-MB-231 Xenografts in Nude Mice by Modulating the Hedgehog Pathway. IJMS 2022;23:10362. [DOI: 10.3390/ijms231810362] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Singh AK, Kumar S. Naringin dihydrochalcone potentially binds to catalytic domain of matrix metalloproteinase-2: molecular docking, MM-GBSA, and molecular dynamics simulation approach. Natural Product Research. [DOI: 10.1080/14786419.2022.2118746] [Reference Citation Analysis]
9 Singh AK, Kumar S. Naringin dihydrochalcone potentially binds to catalytic domain of matrix metalloproteinase-2: molecular docking, MM-GBSA, and molecular dynamics simulation approach. Nat Prod Res 2022;:1-5. [PMID: 36047975 DOI: 10.1080/14786419.2022.2118746] [Reference Citation Analysis]
10 Singh AK, Kumar S. Naringin dihydrochalcone potentially binds to catalytic domain of matrix metalloproteinase-2: molecular docking, MM-GBSA, and molecular dynamics simulation approach. Natural Product Research 2022. [DOI: 10.1080/14786419.2022.2118746] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Baidya SK, Banerjee S, Adhikari N, Jha T. Selective Inhibitors of Medium-Size S1' Pocket Matrix Metalloproteinases: A Stepping Stone of Future Drug Discovery. J Med Chem 2022. [PMID: 35969157 DOI: 10.1021/acs.jmedchem.1c01855] [Reference Citation Analysis]
12 Gonçalves PR, Nascimento LD, Gerlach RF, Rodrigues KE, Prado AF. Matrix Metalloproteinase 2 as a Pharmacological Target in Heart Failure. Pharmaceuticals (Basel) 2022;15:920. [PMID: 35893744 DOI: 10.3390/ph15080920] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
13 Zhang W, Lu C, Cai S, Feng Y, Shan J, Di L. Aconiti Lateralis Radix Praeparata as Potential Anticancer Herb: Bioactive Compounds and Molecular Mechanisms. Front Pharmacol 2022;13:870282. [PMID: 35662730 DOI: 10.3389/fphar.2022.870282] [Reference Citation Analysis]
14 Belal A, Elanany MA, Santali EY, Al-Karmalawy AA, Aboelez MO, Amin AH, Abdellattif MH, Mehany ABM, Elkady H. Screening a Panel of Topical Ophthalmic Medications against MMP-2 and MMP-9 to Investigate Their Potential in Keratoconus Management. Molecules 2022;27:3584. [PMID: 35684529 DOI: 10.3390/molecules27113584] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
15 Morris RM, Mortimer TO, O'Neill KL. Cytokines: Can Cancer Get the Message? Cancers (Basel) 2022;14:2178. [PMID: 35565306 DOI: 10.3390/cancers14092178] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
16 Li T, Cao H, Wu S, Zhong P, Ding J, Wang J, Wang F, He Z, Huang G. Phosphorylated ATF1 at Thr184 promotes metastasis and regulates MMP2 expression in gastric cancer. J Transl Med 2022;20. [DOI: 10.1186/s12967-022-03361-3] [Reference Citation Analysis]
17 Nicolai A, Taurone S, Carradori S, Artico M, Greco A, Costi R, Scarpa S. The kinesin Eg5 inhibitor K858 exerts antiproliferative and proapoptotic effects and attenuates the invasive potential of head and neck squamous carcinoma cells. Invest New Drugs. [DOI: 10.1007/s10637-022-01238-2] [Reference Citation Analysis]
18 Das S, Amin SA, Gayen S, Jha T. Insight into the structural requirements of gelatinases (MMP-2 and MMP-9) inhibitors by multiple validated molecular modelling approaches: Part II. SAR QSAR Environ Res 2022;33:167-92. [PMID: 35301933 DOI: 10.1080/1062936X.2022.2041722] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Verhulst E, Garnier D, De Meester I, Bauvois B. Validating Cell Surface Proteases as Drug Targets for Cancer Therapy: What Do We Know, and Where Do We Go? Cancers (Basel) 2022;14:624. [PMID: 35158891 DOI: 10.3390/cancers14030624] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Das S, Amin SA, Datta S, Adhikari N, Jha T. Synthesis, biological activity, structure activity relationship study and liposomal formulation development of some arylsulfonyl pyroglutamic acid derivatives. Journal of Molecular Structure 2022;1248:131512. [DOI: 10.1016/j.molstruc.2021.131512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Khalil HH, Osman HA, Teleb M, Darwish AI, Abu-Serie MM, Khattab SN, Haiba NS. Engineered s-Triazine-Based Dendrimer-Honokiol Conjugates as Targeted MMP-2/9 Inhibitors for Halting Hepatocellular Carcinoma. ChemMedChem 2021. [PMID: 34547831 DOI: 10.1002/cmdc.202100465] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Das S, Amin SA, Jha T. Insight into the structural requirement of aryl sulphonamide based gelatinases (MMP-2 and MMP-9) inhibitors - Part I: 2D-QSAR, 3D-QSAR topomer CoMFA and Naïve Bayes studies - First report of 3D-QSAR Topomer CoMFA analysis for MMP-9 inhibitors and jointly inhibitors of gelatinases together. SAR QSAR Environ Res 2021;32:655-87. [PMID: 34355614 DOI: 10.1080/1062936X.2021.1955414] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]